Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2019.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Efficacy and Tolerability of Prostaglandin Analogues in Treating Systemic Sclerosis-Associated Raynaud Phenomenon: A Systematic Review and Meta-Analysis.
Int J Rheumatol
December 2024
Toronto Scleroderma Program, Schroeder Arthritis Institute, Toronto Western Hospital, Toronto, Ontario, Canada.
Systemic sclerosis-associated Raynaud phenomenon (SSc-RP) confers poor outcomes, including ulceration, gangrene, autoamputation, and hand disability. Prostaglandin analogues (PG) are a group of prostacyclin-derived drugs with properties that may address underlying complex mechanisms of SSc-RP. This systematic review and meta-analysis evaluated the efficacy and tolerability of PGs in SSc-RP.
View Article and Find Full Text PDFPostoperative unexplained sigmoid stenosis in a patient with rectal cancer complicated with connective tissue disease: a case report and literature review.
Front Oncol
December 2024
Department of General Surgery, General Hospital of Northern Theater Command, Shenyang, China.
It is well established that host immunity plays a critical role in defending against colorectal cancer (CRC) progression. Connective tissue disease (CTD) encompasses a group of heterogeneous, immune-mediated disorders that present with diverse and often non-specific initial symptoms. Raynaud's phenomenon is a common feature, complicating early diagnosis.
View Article and Find Full Text PDFLymphoplasmacytic Lymphoma Presenting as Severe Secondary Raynaud's Phenomenon.
Cureus
November 2024
Division of Allergy, Clinical Immunology, & Rheumatology, University of Kansas Medical Center, Kansas City, USA.
Primary Raynaud's phenomenon (RP) is a common and self-limiting condition, which is not secondary to any other disease process. In contrast, secondary RP has an underlying etiology. Several conditions can lead to secondary RP, which creates a challenging landscape for clinicians.
View Article and Find Full Text PDFBiological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of SSc (VEDOSS).
Rheumatology (Oxford)
December 2024
Leeds Institute of Rheumatic and Musculoskeletal Medicine and Biomedical Research Centre, University of Leeds.
Objective: The Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR study showed that, despite not showing any clinical sign of disease, patients with Raynaud's and antinuclear antibodies and/or capillaroscopy abnormalities often progress to systemic sclerosis (SSc) within 5 years. We aimed to determine whether VEDOSS biosamples show biological SSc activity pre-clinically.
Methods: Skin biopsies were histologically analysed.
[COVID-19 vaccines efficacy and infection features in patients with systemic sclerosis: A single-center cohort study].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
Objective: To comprehensively understand the COVID-19 vaccination and infection status among patients with systemic sclerosis (SSc).
Methods: We conducted a retrospective analysis of patients diagnosed with SSc who were hospitalized in the Rheumatology and Immunology Department of Peking University People' s Hospital from January 2016 to March 2023. We collected detailed clinical cha-racteristics, vaccination status, and infection details through a systematic review of medical records and telephone follow-ups with the SSc patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!